All In Biotech

Drug Trial Radar · NCT06077760

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 868 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

868

Planned (sponsor's estimate)

Start

Dec 6, 2023

Primary completion

Jun 25, 2030

Study completion Dec 21, 2035

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
ModernaTX, Inc.
First posted
Oct 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Intismeran autogeneBiological

    IM injection

  • PembrolizumabBiological

    IV infusion

  • PlaceboOther

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease- Free Survival (DFS)Time frame: Up to ~78 months

Locations

229 sites in 33 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology ( Site 0039)

    Anchorage, Alaska

  • The University of Arizona Cancer Center - North Campus ( Site 0071)

    Tucson, Arizona

  • YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020)

    Yuma, Arizona

  • UCLA Clinical & Translational Research Center (CTRC) ( Site 0059)

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian ( Site 4042)

    Newport Beach, California

  • Hoag Memorial Hospital Presbyterian ( Site 4048)

    Newport Beach, California

  • St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0074)

    Orange, California

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0030)

    Orange, California

  • UCHealth Memorial Hospital-Heme Onc ( Site 0052)

    Colorado Springs, Colorado

  • George Washington University Medical Faculty Associates ( Site 4064)

    Washington D.C., District of Columbia

  • Mayo Clinic Florida ( Site 4043)

    Jacksonville, Florida

  • Miami Cancer Institute at Baptist Health, Inc. ( Site 4047)

    Miami, Florida

  • Mid Florida Hematology and Oncology Center ( Site 0014)

    Orange City, Florida

  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0013)

    Orlando, Florida

  • Moffitt Cancer Center ( Site 0078)

    Tampa, Florida

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0012)

    Marietta, Georgia

  • Southeastern Regional Medical Center ( Site 0098)

    Newnan, Georgia

  • Beacon Cancer Care ( Site 0044)

    Post Falls, Idaho

  • Illinois Cancer Care ( Site 7003)

    Peoria, Illinois

  • University of Iowa-Holden Comprehensive Cancer Center ( Site 0062)

    Iowa City, Iowa

  • Saint Elizabeth Healthcare ( Site 0092)

    Edgewood, Kentucky

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0037)

    Louisville, Kentucky

  • LSU Health Baton Rouge North Clinic ( Site 4040)

    Baton Rouge, Louisiana

  • Our Lady of the Lake ( Site 4050)

    Baton Rouge, Louisiana

  • University of Michigan Clinical Trials Office ( Site 0058)

    Ann Arbor, Michigan

  • Cancer and Hematology Centers of Western Michigan ( Site 4003)

    Grand Rapids, Michigan

  • St. Vincent Frontier Cancer Center ( Site 0043)

    Billings, Montana

  • NHO Revive Research Institute, LLC ( Site 4009)

    Lincoln, Nebraska

  • Memorial Sloan Kettering - Basking Ridge ( Site 4056)

    Basking Ridge, New Jersey

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0036)

    Hackensack, New Jersey

  • Memorial Sloan Kettering - Monmouth ( Site 4057)

    Middletown, New Jersey

  • Memorial Sloan Kettering - Bergen ( Site 4059)

    Montvale, New Jersey

  • Atlantic Health Morristown Medical Center ( Site 4018)

    Morristown, New Jersey

  • New York Oncology Hematology, P.C. ( Site 4012)

    Albany, New York

  • Memorial Sloan-Kettering Cancer Center at Commack ( Site 4055)

    Commack, New York

  • Memorial Sloan Kettering - Westchester ( Site 4058)

    Harrison, New York

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island-Clinical Research Department ( Site 0095)

    Mineola, New York

  • The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 4053)

    New York, New York

  • Laura and Isaac Perlmutter Cancer Center ( Site 0010)

    New York, New York

  • Icahn School of Medicine at Mount Sinai ( Site 0034)

    New York, New York

Showing 40 of 229 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.